Sun Pharmaceutical Industries Ltd
SUNPHARMA price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- SUNPHARMA
- MB Code
- MBEQU5368
- ISIN
- INE044A01036
- BSE code
- 524715
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 14611.79 Cr
- Net profit
- 2723.72 Cr
- EPS
- 11.3
- YoY revenue
- +12.76%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for SUNPHARMA
Sun Pharma reported Q4 FY26 PAT up 26.2% YoY to Rs 2,714 crore, revenue rose 13.6% to Rs 14,559.8 crore, and the board recommended a fina…
EPS 11.30 vs est. 11.25
Beat estimates by 0.48%
Sun Pharma reported Q4 net profit up 26% to Rs 2,714 crore and its board proposed a Rs 5 final dividend, with India formulations sales ri…
Sun Pharma reported a 26% rise in Q4 net profit, highlighting stronger quarterly earnings for the pharma major. The article does not prov…
Sun Pharma is exploring Eurobonds and bond swaps to help finance its planned US-based Organon acquisition, with bankers saying it may rai…
On 28 Apr 2026 Sun Pharma agreed to buy Organon for $11.75 billion after three months of near-daily talks; deal needs approvals across ju…
On 28 Apr 2026 Sun Pharma announced a $11.75bn acquisition of Organon, signalling a strategic shift from US generics to geographic divers…
On April 27, 2026 Sun Pharma signed a definitive agreement to acquire Organon for $11.75B, using cash and bank financing, shifting it to …
Price returns
Historical performance
Technicals
Indicator consensus